Member

In introducing the intent of this instrument, the Minister discussed the idea of greater transparency. Like the noble Baroness, Lady Bennett, we welcome the fact that clinical trials will be required to be registered on a public database—and not only the positive results but the negative results too. We can always learn from things that went wrong and not downplay them; when mistakes have been made, we can learn from them. Increased transparency is crucial for public trust. There is, I suspect, a need to ensure that sensitive information, such as proprietary data or details that could affect patient confidentiality, are handled properly. What safeguards will be in place to protect the interests of participants and sponsors while promoting greater transparency?